News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catabasis Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of Lead Compound CAT-1004


10/5/2011 10:14:09 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, today announced the initiation of a Phase 1 clinical trial for its lead product candidate CAT-1004. The compound, a novel conjugate of the essential omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, is being developed to treat patients with type 2 diabetes. The current study will evaluate the safety, tolerability and pharmacokinetic profile of CAT-1004 in healthy adult subjects.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES